Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes

Diabetes Care

Volumn 31, Issue 1, 2008, Pages 44-46

  Swan, Karena L ^a   Weinzimer, Stuart A ^a   Dziura, James D ^b   Steil, Garry M ^c   Voskanyan, Gayane R ^c   Steffen, Amy T ^a   Martin, Melody L ^a   Tamborlane, William V ^a,b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDTRONIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG MECHANISM; GLUTEUS MAXIMUS MUSCLE; HOSPITAL ADMISSION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INTRAVENOUS CATHETER; PREPUBERTY; SCHOOL CHILD; AGING; BLOOD; CHILD; GLUCOSE CLAMP TECHNIQUE; INSULIN INFUSION; PUBERTY; REFERENCE VALUE;

ADOLESCENT; AGING; CHILD; DIABETES MELLITUS, TYPE 1; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; INSULIN INFUSION SYSTEMS; PUBERTY; REFERENCE VALUES;

EID: 38149091855     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-0737     Document Type: Article

References (10)

1. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
2. Mudaliar S, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, Henry RR: Insulin aspart (B28 Asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 22:1501-1506, 1999
3. Becker RHA, Frick A, Wessels D, Scholtz H: Evaluation of the pharmacodynamic and pharmacokinetic profiles of insulin glulisine-a novel, rapid-acting, human insulin analogue (Abstract). Diabetologia 46:775, 2003
4. Becker RHA, Frick AD, Kapitza C, Heise T, Rave K: Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine (GLU) versus insulin lispro (IL) and regular human insulin (RHI) in patients with type 2 diabetes (Abstract). Diabetes 53 (Suppl. 2):A119, 2004
5. Danne T, Becker RHA, Heise T, Bittner C, Frick AD, Rave K: Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 28:2100-2105, 2005
6. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV: Impaired insulin action in puberty: a contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 315:215-219, 1986
7. Amiel SA, Caprio S, Sherwin RS, Plewe G, Haymond MW, Tamborlane WV: Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 72:277-282, 1991
8. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
9. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T: Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 21:1910-1914, 1998
10. Bloch CA, Clemmons P, Sperling MA: Puberty reduces insulin sensitivity. J Pediatr 110:481-487, 1987